MTOR and cancer: The phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in many human cancers, and inhibition of the mTOR pathway as a new therapeutic target is an active area of research (Frattini et al, 2005; Velho et al, 2005).